Quell Therapeutics Significantly Expands Clinical Manufacturing Capacity for its Engineered Treg Cell Therapies through a Collaboration with the Cell and Gene Therapy Catapult

Collaboration to facilitate an expanded manufacturing footprint to enable clinical supply of Quell’s pipeline, including QEL-001 in liver transplantation and pipeline programs in neuroinflammation and autoimmunity.

Dr John Brown, CBE to retire as Cell and Gene Therapy Catapult’s Chairman

John Brown will retire at the end of 2021 after nine years in the role. Dr John Brown, CBE, FRSE, Chairman of Cell and Gene Therapy Catapult (CGT Catapult), will retire from the role at the end of 2021 after completing three successive terms. The Nomination Committee will establish a process, led by Hilary Newiss, to identify and appoint his successor in due course.

Metrion Biosciences expands into new headquarters to support continued growth

• New 12,000 sq. ft Granta Park, Cambridge (UK) premises more than doubles Metrion’s laboratory space • Custom designed laboratories support new GLP cardiac safety services, expanded cell biology facilities and 384-well automated electrophysiology capability

Coulter Partners secures Chief Executive Officer for Civetta

Cambridge, MA – 21 September 2021 – Coulter Partners, a global Life Sciences, Health and Technology executive search specialist, was delighted to partner with Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, to secure the appointment of Christopher D. Roberts, Ph.D., as Chief Executive Officer.

CEO Update | 20 September 2021

The Prime Minister and the Health Secretary announced the Government’s COVID-19 plan for the Autumn and Winter months.  The Government still sees vaccines as the UK’s best defence to avoid any further lockdowns and I was interested to note in the press release that ‘building this defence’ will involve pharmaceutical interventions, which I’m sure will include further work in antibody therapies and antivirals.

ARECOR ANNOUNCES POSITIVE HEADLINE RESULTS FROM FIRST PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN CANDIDATE FOR DIABETES

AT278 delivers significantly accelerated PK/PD profile compared to NovoRapid® Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices Potential to enable more effective disease management for insulin resistant patients requiring >200 units of insulin per day

Guest Blog | The Talent Vaccine

Dr Jen Vanderhoven, Director of Teesside University’s National Horizons Centre talks about the work being done to establish the UK’s training provision for vaccine manufacturing, advanced therapies and bioprocessing.

BIA blog | Government reshuffle 2021

As many of you will have spotted on the news, Boris Johnson held a major reshuffle last week. While the headlines have mainly focused on the departure of Dominic Raab and Gavin Williamson, there are also some important changes for life sciences. 

Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly

Demand for Touchlight’s proprietary synthetic DNA vector, dbDNA™, has grown rapidly in the last year. The latest aspect of its ongoing fundraise will be used to support Touchlight in its mission to be the world’s leading synthetic DNA manufacturer and drive the genetic medicine revolution.

AAV reference material to be produced at the Cell and Gene Therapy Catapult Braintree in collaboration with the National Institute for Biological Standards and Control

London, UK, 16th September 2021 – A 6-month collaborative project was announced today that will help to accelerate the introduction of regulated advanced gene therapies that use Adenovirus-associated vectors (AAVs).